摘要
1 文献来源Awad MM,Gadgeel SM,Borghaei H,et al.Longterm overall survival from KEYNOTE-021 cohort G:Pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC [J].J Thorac Oncol,2021,16(1):162-168.2 证据水平1b。
作者
周建娅
周建英
ZHOU Jian-ya;ZHOU Jian-ying(Department of Respiratory Diseases,The First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310003,China)
出处
《循证医学》
2021年第4期208-213,共6页
The Journal of Evidence-Based Medicine
基金
默沙东(中国)投资有限公司的支持。
关键词
帕博利珠单抗
化学治疗
晚期非鳞状非小细胞肺癌
长期生存
一线治疗
pembrolizumab
chemotherapy
advanced non-squamous non-small cell lung cancer
long-term survival
first-line therapy
